Latest Content

FDA Grants BTD to the ADC GSK’227 in Relapsed/Refractory Osteosarcoma

January 9th 2025, 10:00pm

By Ryan Scott

Article

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with relapsed/refractory osteosarcoma.

Laparoscopic Wedge and Endoscopic Resection Are Safe, Feasible in Gastric GISTs

January 9th 2025, 8:00pm

By Ryan Scott

Article

Both laparoscopic wedge and endoscopic resection are safe and feasible treatment approaches for patients with gastric gastrointestinal stromal tumors.

A New Year, A New Approach to Survivorship After Cancer

January 9th 2025, 6:00pm

By Felicia Mitchell

Article

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and my hopes for the future.

Minoxidil May Safely Aid in Hair Growth for Patients With Breast Cancer

January 9th 2025, 4:00pm

By Alex Biese

Article

Low-dose oral minoxidil, the hair growth drug that is the active ingredient in Rogaine, may be safe and effective for patients with breast cancer.

Real-World Data May Support Opdivo Plus Yervoy Efficacy in mRCC

January 9th 2025, 2:00pm

By Spencer Feldman

Article

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC

January 8th 2025, 10:00pm

By Alex Biese

Article

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.

Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors

January 8th 2025, 8:00pm

By Ryan Scott

Article

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.

My Top 10 Hacks for Surviving with Cancer in the Infusion Room

January 8th 2025, 6:00pm

By Kelly Irvin

Article

Every treatment bag should include an unlimited supply of humor. Stuff will happen. It’ll be hard, but you may learn to laugh about it later, like I did.

Psilocybin May Have Mental Health Benefits for Patients With Cancer

January 8th 2025, 4:00pm

By Alex Biese

Video

CURE spoke with an expert about the potential positive effects of psilocybin-assisted psychotherapy.

Polycythemia Vera: How to Diagnose

January 8th 2025, 3:23pm

By Julie Huynh-Lu, P.A.

Video

A panelist discusses how patients with polycythemia vera (PV) often present with diverse symptoms ranging from fatigue and itching to cardiovascular complications, leading doctors to conduct specific diagnostic tests including complete blood counts, JAK2 mutation analysis and bone marrow biopsies, although diagnosis can be challenging due to symptom overlap with other conditions and varying presentation patterns.

BLA Has Been Submitted For Kidney Cancer Imaging PET Product Zircaix

January 8th 2025, 2:00pm

By Ryan Scott

Article

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.

Coming to Terms With Hair Loss After Chemotherapy

January 7th 2025, 10:00pm

By Amy Brewster

Article

Losing my hair after chemo was devastating, and I struggled to accept how it changed my appearance and self-image.

Stereotactic Body Radiation May Improve Survival in Liver Cancer Subset

January 7th 2025, 8:14pm

By Spencer Feldman

Article

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.

A Year of Resilience: Looking Back After a Myeloma Diagnosis

January 7th 2025, 6:00pm

By Ronald Chin

Article

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.

CBD Use Found to Be Safe Among Patients with Breast Cancer, Prompts Further Study

January 7th 2025, 4:00pm

By Alex Biese

Article

CBD consumption was safe but did not have a statistically significant reduction in scan-related anxiety versus placebo for patients with breast cancer.